This is a multi-center, single-arm, prospective study to enroll patients diagnosed as pulmonary arterial hypertension. The objective in this study is to observe the efficacy and safety of treprostinil in subjects with pulmonary arterial hypertension.
No linked publications found in PubMed
Inclusion Criteria: * Diagnosed with symptomatic idiopathic or heritable PAH classified as WHO functional class III and IV symptoms. * PAH patient, who met NHI criteria, will be scheduled to receive subcutaneous/intravenous treprostinil treatment. * Ability to adhere to the study visit schedule and understand and comply with all protocol requirements. * Will provide completed and signed written informed consents Exclusion Criteria: * Active treatment with injectable prostanoids different from subcutaneous/intravenous treprostinil